Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

Publication date: Available online 5 December 2019Source: The LancetAuthor(s): Frank A Vicini, Reena S Cecchini, Julia R White, Douglas W Arthur, Thomas B Julian, Rachel A Rabinovitch, Robert R Kuske, Patricia A Ganz, David S Parda, Michael F Scheier, Kathryn A Winter, Soonmyung Paik, Henry M Kuerer, Laura A Vallow, Lori J Pierce, Eleftherios P Mamounas, Beryl McCormick, Joseph P Costantino, Harry D Bear, Isabelle GermainSummaryBackgroundWhole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation.MethodsWe did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to rece...
Source: The Lancet - Category: General Medicine Source Type: research

Related Links:

Publication date: June 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 6Author(s): Ashleigh Bell, Sheena Waters, Yousif Shanshal, Robert Milligan
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Objective: The aim of the study was to quantify baseline estradiol (E2) and estrone (E1) concentrations according to selected patient characteristics in a substudy nested within the MAP.3 chemoprevention trial. Methods: E2 and E1 levels were measured in 4,068 postmenopausal women using liquid chromatography-tandem mass spectrometry. Distributions were described by age, years since menopause, race, body mass index (BMI), smoking status, and use and duration of hormone therapy using the Kruskal-Wallis test. Multivariable linear regression was also used to identify characteristics associated with estrogen levels. Result...
Source: Menopause - Category: OBGYN Tags: Original Studies Source Type: research
Conclusion: The decline in ET utilization had differential disease and expenditure consequences by age groups in the United States. These results are limited by the lack of inclusion of vasomotor symptom benefit and costs of alternative medications for these symptoms in the analysis.
Source: Menopause - Category: OBGYN Tags: Original Studies Source Type: research
CONCLUSION: We successfully demonstrated that a higher HEI-2015 score was associated with a reduced breast cancer risk. PMID: 32458645 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
n Su Choi We evaluated the heterogeneity of the effect of known risk factors on breast cancer development based on breast density by using the Breast Imaging-Reporting and Data System (BI-RADS). In total, 4,898,880 women, aged 40–74 years, who participated in the national breast cancer screening program in 2009–2010 were followed up to December 2018. Increased age showed a heterogeneous association with breast cancer (1-year hazard ratio (HR) = 0.92, 1.00 (reference), 1.03, and 1.03 in women with BI-RADS density category 1, 2, 3, and 4, respectively; P-heterogeneity < 0.001). More advanced ag...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract Background: As tumors maintain an inflammatory microenvironment, anti-inflammatory medication can be useful in cancer therapy. We have previously shown an association with improved survival in melanoma for use of the H1-antihistamines desloratadine and loratadine, and here we examine use of H1-antihistamines and breast cancer mortality.Material and methods: We investigated use of the six major H1-antihistamines (cetirizine, clemastine, desloratadine, ebastine, fexofenadine and loratadine) and breast cancer-specific and overall mortality in a nation-wide register-based study of all 61,627 Swedish women dia...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Publication date: Available online 24 May 2020Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Armina Kazi, Olga Goloubeva, Amanda Schech, Stephen Yu, Gauri J Sabnis
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
This study also focuses the idea that estrogen receptor cased subtypes of cancer may have different molecular environments which has an impact on the therapeutic efficacy. PMID: 32449069 [PubMed - as supplied by publisher]
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Tags: Mol Biol Rep Source Type: research
Abstract BACKGROUND: Survivorship care plans (SCPs) have been used to address ongoing health problems associated with the diagnosis and treatment of early-stage breast cancer. OBJECTIVES: The aim of this article was to determine whether nurse-led consultations using SCPs, as compared with a standard medical consultation, identify more side effects and supportive care needs and lead to appropriate referral patterns. METHODS: The study audited 160 retrospective medical clinic and nursing SCP records in a sample of patients receiving treatment for early-stage breast cancer at a tertiary-level breast service...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin J Oncol Nurs Source Type: research
ConclusionOverweight/obese breast cancer patients may be more prone to breast WAT inflammation and may be associated with abnormalities in circulatory markers associated with metabolic syndrome.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Brachytherapy | Breast Cancer | Breast Conservation Surgery | Breast Lumpectomy | Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Department of Health | General Medicine | Hormones | Ireland Health | Israel Health | Lumpectomy | Mastectomy | Men | Menopause | Middle East Health | Radiation Therapy | Statistics | Toxicology | Women